These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38553321)

  • 1. Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-onset Clostridioides difficile Infection.
    Wombwell E; Rosa A
    Clin Ther; 2024 Jun; 46(6):451-454. PubMed ID: 38553321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms.
    Chiu CC; Lin TC; Wu RX; Yang YS; Hsiao PJ; Lee Y; Lin JC; Chang FY
    J Microbiol Immunol Infect; 2017 Dec; 50(6):879-885. PubMed ID: 28087318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital.
    Chastain DB; Ngando I; Bland CM; Franco-Paredes C; Hawkins WA
    Ann Clin Microbiol Antimicrob; 2017 May; 16(1):43. PubMed ID: 28558707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third-Generation Cephalosporin Resistance and Associated Discordant Antibiotic Treatment in Emergency Department Febrile Urinary Tract Infections.
    Mark DG; Hung YY; Salim Z; Tarlton NJ; Torres E; Frazee BW
    Ann Emerg Med; 2021 Sep; 78(3):357-369. PubMed ID: 33781606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefazolin as a predictor of urinary cephalosporin activity in indicated Enterobacterales.
    Bryson AL; Bhalodi A; Liesman RM; Mathers AJ
    J Clin Microbiol; 2024 Apr; 62(4):e0078821. PubMed ID: 38457194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients.
    Uppala A; King EA; Patel D
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1533-1538. PubMed ID: 31114972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of
    Wieczorkiewicz JT; Skinner AM; Cheknis A; Petrella LA; Stevens VW; Wright LM; Gerding DN; Johnson S
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0069824. PubMed ID: 38953622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Susceptibility to first-generation Cephalosporins in Enterobacteriaceae isolated from urine culture according to CLSI and EUCAST breakpoints].
    Corvalán V; Hervé B; Sanhueza C; Martínez N; Almonacid M; Fuente S
    Rev Chilena Infectol; 2018; 35(3):329-331. PubMed ID: 30534916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and risk factors for extended-spectrum β-lactamase producing antimicrobial-resistant
    Omar MH; Kilale AM; Rashid HK; Mwakapeje ER; Onoka IM; Gimbi AA
    Pan Afr Med J; 2024; 47():193. PubMed ID: 39119113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reanalysis of cefazolin surrogate susceptibility breakpoints utilized as guidances for oral cephalosporin treatments of uncomplicated urinary tract infections: caution concerning application to cefadroxil.
    Nguyen HM; Jones RN
    Diagn Microbiol Infect Dis; 2020 Jul; 97(3):115053. PubMed ID: 32349909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
    Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
    Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary Evaluation of Tebipenem
    Mendes RE; Arends SJR; Streit JM; Critchley I; Cotroneo N; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0205722. PubMed ID: 36625644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of inpatient versus outpatient resistance patterns of pediatric urinary tract infection.
    Saperston KN; Shapiro DJ; Hersh AL; Copp HL
    J Urol; 2014 May; 191(5 Suppl):1608-13. PubMed ID: 24679887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Resistance Patterns of Urinary Tract Infection in Al-Madinah Al-Munawarah, Saudi Arabia: A Retrospective Study.
    Alhhazmi AA; Alhazmi RA; Alahmadi ES; Almuallim WM; Aljurfi ZI; Alturkostani MA
    Discov Med; 2024 Apr; 36(183):853-864. PubMed ID: 38665033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.
    Webb BJ; Subramanian A; Lopansri B; Goodman B; Jones PB; Ferraro J; Stenehjem E; Brown SM
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964789
    [No Abstract]   [Full Text] [Related]  

  • 18. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection.
    Farrell DJ; Morrissey I; De Rubeis D; Robbins M; Felmingham D
    J Infect; 2003 Feb; 46(2):94-100. PubMed ID: 12634070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections.
    Wu YH; Chen PL; Hung YP; Ko WC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):197-203. PubMed ID: 23063776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.